Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial

Abstract

ObjectiveThis study aimed to evaluate the effect of three days of GnRH antagonist pretreatment on the pregnancy outcomes of women with polycystic ovarian syndrome (PCOS) on GnRH antagonist protocols for IVF/ICSI.MethodsFifty women with PCOS in the control group received conventional antagonist protocols, starting on day 2 of the cycle. In the pretreatment group (n=38), a GnRH antagonist was administered from day 2 of the menstrual cycle for three days.ResultsControlled ovarian stimulation (COS) duration and gonadotropin dosages were similar in both groups. The number of metaphase II (MII) oocytes, 2PN oocytes, embryos, along with implantation and clinical pregnancy rates, were higher in the pretreatment group when compared with controls, although the increment was not significant (P value ≥0.05). The chemical pregnancy rate was significantly higher in the pretreatment group. The rate of OHSS was significantly lower in the pretreatment than in the control group.ConclusionWomen with PCOS offered early follicular phase GnRH antagonist pretreatment for three consecutive days had significantly fewer cases of OHSS and higher chemical pregnancy rates. There were trends toward greater numbers of MII oocytes, 2PN oocytes, and embryos, and higher clinical pregnancy rates in the pretreatment group.

Controlled ovarian stimulation therapy as a potential risk for the development and progression of renal cell carcinomas: A case report and literature review

“…As a result of this treatment, multiple mature oocytes can be retrieved, fertilized in vitro, and implanted, increasing the chances of a live birth. In particular, and similar to our case, patients undergoing fertility stimulation therapy usually receive follitropin alfa, HCG, leuprolide (injectable treatment), and cetrotide (11)(12)(13)(14). Follitropin alfa, or follicle-stimulating hormone (FSH), is a hormone promoting the development and maturation of oocytes in the ovaries (11).…”

“…Leuprolide is a synthetic gonadotropin-releasing hormone (GnRH) (13). Cetrotide is used to block the hormone GnRH to be released from the ovaries, regulating hormone responses in women during fertility treatments (14). Direct morbidity and mortality related to IVF are relatively low.…”

Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in normal ovulatory women undergoing IVF/ICSI: a randomized controlled trial

“…A meta-analysis of the delayed initiation of antagonist pretreatment for low-response patients showed that this measure reduces the Gn dose and increases the clinical pregnancy rate. Studies have also found that pretreatment with antagonists in PCOS patients can increase the biochemical pregnancy rate and significantly reduce the incidence of OHSS [ 27 ]. Patients with PCOS and poor responders were excluded from the study The influence of different ovarian reactions on the results can be excluded, thus making the research data more reliable.…”

Evaluation of GnRH antagonist pre-treatment before ovarian stimulation in a delayed-start antagonist protocol in normal ovulatory women undergoing IVF/ICSI: a randomized controlled trial (RCT)

“…A meta-analysis of the delayed initiation of antagonist pre-treatment for low-response patients showed that this measure reduces the Gn dose and increases the clinical pregnancy rate. Studies have also found that pre-treatment with antagonists for PCOS patients can increase the biochemical pregnancy rate and signi cantly reduce the incidence of OHSS [27]. PCOS and poor responders were excluded from the patients enrolled in this study.…”